Daiwa Securities Group Inc. Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Daiwa Securities Group Inc. boosted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 10.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 30,694 shares of the biopharmaceutical company’s stock after purchasing an additional 3,000 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Royalty Pharma were worth $868,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Aurora Investment Counsel increased its holdings in shares of Royalty Pharma by 1.0% in the 3rd quarter. Aurora Investment Counsel now owns 50,441 shares of the biopharmaceutical company’s stock worth $1,427,000 after buying an additional 512 shares during the last quarter. Xponance Inc. grew its position in Royalty Pharma by 1.9% in the second quarter. Xponance Inc. now owns 31,704 shares of the biopharmaceutical company’s stock worth $836,000 after acquiring an additional 606 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Royalty Pharma by 32.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 655 shares during the last quarter. Values First Advisors Inc. raised its position in Royalty Pharma by 7.6% during the third quarter. Values First Advisors Inc. now owns 10,412 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 738 shares during the period. Finally, Phillips Wealth Planners LLC lifted its stake in shares of Royalty Pharma by 10.2% in the 3rd quarter. Phillips Wealth Planners LLC now owns 8,733 shares of the biopharmaceutical company’s stock valued at $246,000 after purchasing an additional 808 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

RPRX stock opened at $26.66 on Friday. Royalty Pharma plc has a twelve month low of $25.10 and a twelve month high of $31.66. The firm has a market cap of $15.71 billion, a price-to-earnings ratio of 13.81, a PEG ratio of 4.67 and a beta of 0.47. The business’s fifty day simple moving average is $27.15 and its two-hundred day simple moving average is $27.33. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.64.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $0.21 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a yield of 3.15%. Royalty Pharma’s payout ratio is 43.52%.

Analyst Upgrades and Downgrades

RPRX has been the topic of several analyst reports. Citigroup cut their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. The Goldman Sachs Group boosted their price objective on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.